Search Results 651-660 of 21550 for Inhibition
... inhibition. We hypothesize that targeting melanoma with a PD-1 (MC9324) CAR TIL therapy would capitalize on the tumor homing machinery of the TIL to drive ...
... inhibitor quemliclustat, and chemotherapy in the second-line (2L) or greater setting in participants with locally advanced unresectable or metastatic ...
Rosuvastatin belongs to a group of medicines called HMG-CoA reductase inhibitors, or statins. It works by blocking an enzyme that is needed by the body to ...
Prior anticancer therapy is allowed (excluding approved or investigational Trk, ROS1, or ALK (non-NSCLC patients only) inhibitors in patients who have tumors ...
Li LX, Zhou JX, Li X. Authors' Reply: Deciphering the Cell-Specific Specificity of the a-Klotho-Cellular Inhibitor ... Sirtuin 1 inhibition delays cyst formation ...
Prior receipt of a selective FGFR inhibitor. History of and/or current ... Use of any potent CYP3A4 inhibitors or inducers within 14 days or 5 half ...
Patients may not require concomitant use of known strong CYP3A inhibitors (e.g., itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with
Ibrexafungerp is a novel glucan synthase inhibitor currently undergoing phase II and phase III clinical trials. This compound has demonstrated in vitro ...
The goal of this project is to determine which patients with this cancer will respond to inhibitors. The researchers hope to develop a chemical assay that ...
It is also used alone or together with other medicines to treat homozygous familial hypercholesterolemia (HoFH). Rosuvastatin is an HMG-CoA reductase inhibitor ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.